NCT05745883 - Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

May 31, 2026

Conditions

Chronic Kidney DiseasesAnemia of Chronic Kidney Disease

Interventions

DRUG

DISC-0974

DISC-0974 is administered subcutaneously

DRUG

Placebo

Placebo is administered subcutaneously

Trial Locations (12)

Washington Nephrology Associates, LLP, Alexandria

Nephrology and Hypertension Specialists, PC-Dalton, Dalton

Accel Research, DeLand

Flourish Research, Winter Park

Total Research Group, Miami

Centricity Research, Columbus

Center for Advanced Kidney Research PLC, Saint Clair Shores

Mayo Clinic, Rochester

Clinical Advancement Center, PLLC, San Antonio

Endeavor Clinical Trials, San Antonio

Rocky Mountain Kidney Care - Lone Tree, Lone Tree

Boise Kidney & Hypertension PLLC, Nampa